Nano Dimension Shares Slide on Plan to Combine With Healthcare AI Firm

Dow Jones06-15

By Doc Louallen

Nano Dimension shares fell after the company said it signed a nonbinding term sheet to combine with Infinite Epigenetics, shifting its focus toward healthcare and artificial intelligence after a strategic review.

Nano shares were down 16% at $1.25 late Monday morning.

If the proposed transaction is completed, the combined company would operate as Infinite Epigenetics and trade on Nasdaq under ticker IEAI. Existing Nano shareholders would hold a minority stake based on a stated value reflecting a 20% premium to Nano's estimated net cash at closing.

Nano and Infinite expect the combined company to have more than $400 million in cash at closing.

Infinite's Chief Executive Dr. Matthew Dawson is expected to lead the combined company.

David Stehlin, chief executive of Nano, told shareholders June 5, the company was nearing the end of a strategic review, narrowing options to high‑growth opportunities and planning to announce a path forward in the coming months. He said Nano streamlined operations and paused buybacks during the review.

Infinite builds AI tools aimed at spotting health risks earlier by reading on/off signals on DNA, an approach known as epigenetics. The companies said the tie-up would give investors a stake in a larger healthcare AI opportunity while using a public-company platform and cash.

Write to Doc Louallen at Doc.Louallen@wsj.com

(END) Dow Jones Newswires

June 15, 2026 11:44 ET (15:44 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2643025772?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-15 23:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643025772","market":"fut","top_or_hot":-1,"title":"Nano Dimension Shares Slide on Plan to Combine With Healthcare AI Firm","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Doc Louallen \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/NNDM\">Nano Dimension</a> shares fell after the company said it signed a nonbinding term sheet to combine with Infinite Epigenetics, shifting its focus toward healthcare and artificial intelligence after a strategic review. \n</p>\n<p>\n  Nano shares were down 16% at $1.25 late Monday morning. \n</p>\n<p>\n  If the proposed transaction is completed, the combined company would operate as Infinite Epigenetics and trade on Nasdaq under ticker IEAI. Existing Nano shareholders would hold a minority stake based on a stated value reflecting a 20% premium to Nano's estimated net cash at closing. \n</p>\n<p>\n  Nano and Infinite expect the combined company to have more than $400 million in cash at closing. \n</p>\n<p>\n  Infinite's Chief Executive Dr. Matthew Dawson is expected to lead the combined company. \n</p>\n<p>\n  David Stehlin, chief executive of Nano, told shareholders June 5, the company was nearing the end of a strategic review, narrowing options to high‑growth opportunities and planning to announce a path forward in the coming months.  He said Nano streamlined operations and paused buybacks during the review. \n</p>\n<p>\n  Infinite builds AI tools aimed at spotting health risks earlier by reading on/off signals on DNA, an approach known as epigenetics. The companies said the tie-up would give investors a stake in a larger healthcare AI opportunity while using a public-company platform and cash. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Doc Louallen at Doc.Louallen@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 15, 2026 11:44 ET (15:44 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nano Dimension Shares Slide on Plan to Combine With Healthcare AI Firm</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNano Dimension Shares Slide on Plan to Combine With Healthcare AI Firm\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-15 23:44</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Doc Louallen \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/NNDM\">Nano Dimension</a> shares fell after the company said it signed a nonbinding term sheet to combine with Infinite Epigenetics, shifting its focus toward healthcare and artificial intelligence after a strategic review. \n</p>\n<p>\n  Nano shares were down 16% at $1.25 late Monday morning. \n</p>\n<p>\n  If the proposed transaction is completed, the combined company would operate as Infinite Epigenetics and trade on Nasdaq under ticker IEAI. Existing Nano shareholders would hold a minority stake based on a stated value reflecting a 20% premium to Nano's estimated net cash at closing. \n</p>\n<p>\n  Nano and Infinite expect the combined company to have more than $400 million in cash at closing. \n</p>\n<p>\n  Infinite's Chief Executive Dr. Matthew Dawson is expected to lead the combined company. \n</p>\n<p>\n  David Stehlin, chief executive of Nano, told shareholders June 5, the company was nearing the end of a strategic review, narrowing options to high‑growth opportunities and planning to announce a path forward in the coming months.  He said Nano streamlined operations and paused buybacks during the review. \n</p>\n<p>\n  Infinite builds AI tools aimed at spotting health risks earlier by reading on/off signals on DNA, an approach known as epigenetics. The companies said the tie-up would give investors a stake in a larger healthcare AI opportunity while using a public-company platform and cash. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Doc Louallen at Doc.Louallen@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 15, 2026 11:44 ET (15:44 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4546","symbol_name":"3D打印","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2643025772","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2643025772","pubTimestamp":1781538240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Nano Dimension shares fell after the company said it signed a nonbinding term sheet to combine with Infinite Epigenetics, shifting its focus toward healthcare and artificial intelligence after a strategic review.Nano shares were down 16% at $1.25 late Monday morning.If the proposed transaction is completed, the combined company would operate as Infinite Epigenetics and trade on Nasdaq under ticker IEAI. Existing Nano shareholders would hold a minority stake based on a stated value reflecting a 20% premium to Nano's estimated net cash at closing.Nano and Infinite expect the combined company to have more than $400 million in cash at closing.David Stehlin, chief executive of Nano, told shareholders June 5, the company was nearing the end of a strategic review, narrowing options to highgrowth opportunities and planning to announce a path forward in the coming months.  He said Nano streamlined operations and paused buybacks during the review.Infinite builds AI tools aimed at spotting health","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4546":"3D打印","ARTY":"ISHARES FUTURE AI & TECH ETF","BK4581":"高盛持仓","BK4161":"工业机械","BK4170":"电脑硬件、储存设备及电脑周边","HAIAU":"Healthcare AI Acquisition Corp","XBI":"SPDR S&P Biotech ETF","LABU":"三倍做多标普生物-Direxion","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","XLV":"健康照护类股ETF-SPDR","BK4588":"碎股","AGIX":"通用人工智能 ETF-AGIX","NNDM":"Nano Dimension Ltd.","BK4585":"ETF&股票定投概念","AIPO":"Defiance AI and Power Infrastructure ETF"},"translate_title":"Nano Dimension股价因计划与医疗保健人工智能公司合并而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGIX":1.5,"XLV":1.5,"ARTY":1.5,"CHAT":1.5,"AIPO":1.5,"NNDM":1.5,"HAIAU":1.5,"XBI":0.6,"LABU":0.6},"content_text":"By Doc Louallen \n\n\n \n\n\nNano Dimension shares fell after the company said it signed a nonbinding term sheet to combine with Infinite Epigenetics, shifting its focus toward healthcare and artificial intelligence after a strategic review. \n\n\n  Nano shares were down 16% at $1.25 late Monday morning. \n\n\n  If the proposed transaction is completed, the combined company would operate as Infinite Epigenetics and trade on Nasdaq under ticker IEAI. Existing Nano shareholders would hold a minority stake based on a stated value reflecting a 20% premium to Nano's estimated net cash at closing. \n\n\n  Nano and Infinite expect the combined company to have more than $400 million in cash at closing. \n\n\n  Infinite's Chief Executive Dr. Matthew Dawson is expected to lead the combined company. \n\n\n  David Stehlin, chief executive of Nano, told shareholders June 5, the company was nearing the end of a strategic review, narrowing options to high‑growth opportunities and planning to announce a path forward in the coming months.  He said Nano streamlined operations and paused buybacks during the review. \n\n\n  Infinite builds AI tools aimed at spotting health risks earlier by reading on/off signals on DNA, an approach known as epigenetics. The companies said the tie-up would give investors a stake in a larger healthcare AI opportunity while using a public-company platform and cash. \n\n\n \n\n\n  Write to Doc Louallen at Doc.Louallen@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 15, 2026 11:44 ET (15:44 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643025772","isCrawlerRequest":true}